Selected article for: "accurately early and acute infection"
Author: Ibrahim, Wadah; Cordell, Rebecca L.; Wilde, Michael J.; Richardson, Matthew; Carr, Liesl; Sundari Devi Dasi, Ananga; Hargadon, Beverley; Free, Robert C.; Monks, Paul S.; Brightling, Christopher E.; Greening, Neil J.; Siddiqui, Salman
Title: Diagnosis of COVID-19 by exhaled breath analysis using gas chromatography–mass spectrometry
  • Cord-id: n9l7ch9s
  • Document date: 2021_7_5
    • ID: n9l7ch9s
    Snippet: BACKGROUND: The ongoing coronavirus disease 2019 (COVID-19) pandemic has claimed over two and a half million lives worldwide so far. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is perceived to be seasonally recurrent, and a rapid noninvasive biomarker to accurately diagnose patients early on in their disease course will be necessary to meet the operational demands for COVID-19 control in the coming years. OBJECTIVE: The aim of this study was to evaluate the role of exh
    Document: BACKGROUND: The ongoing coronavirus disease 2019 (COVID-19) pandemic has claimed over two and a half million lives worldwide so far. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is perceived to be seasonally recurrent, and a rapid noninvasive biomarker to accurately diagnose patients early on in their disease course will be necessary to meet the operational demands for COVID-19 control in the coming years. OBJECTIVE: The aim of this study was to evaluate the role of exhaled breath volatile biomarkers in identifying patients with suspected or confirmed COVID-19 infection, based on their underlying PCR status and clinical probability. METHODS: A prospective, real-world, observational study was carried out, recruiting adult patients with suspected or confirmed COVID-19 infection. Breath samples were collected using a standard breath collection bag, modified with appropriate filters to comply with local infection control recommendations, and samples were analysed using gas chromatography–mass spectrometry (TD-GC-MS). RESULTS: 81 patients were recruited between April 29 and July 10, 2020, of whom 52 out of 81 (64%) tested positive for COVID-19 by reverse transcription–polymerase chain reaction (RT-PCR). A regression analysis identified a set of seven exhaled breath features (benzaldehyde, 1-propanol, 3,6-methylundecane, camphene, beta-cubebene, iodobenzene and an unidentified compound) that separated PCR-positive patients with an area under the curve (AUC): 0.836, sensitivity: 68%, specificity: 85%. CONCLUSIONS: GC-MS-detected exhaled breath biomarkers were able to identify PCR-positive COVID-19 patients. External replication of these compounds is warranted to validate these results.

    Search related documents:
    Co phrase search for related documents
    • accurate rapid and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6
    • accurate rapid and admission point: 1
    • accurate rapid and logistic regression model: 1
    • accurate rapid and low middle: 1, 2
    • accurate rapid and lung cancer: 1, 2
    • accurate rapid and lymphocyte count: 1
    • achieve difficult and acute respiratory distress syndrome: 1, 2
    • achieve difficult and low middle: 1
    • acute respiratory distress syndrome and admission point: 1, 2, 3, 4
    • acute respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory distress syndrome and low middle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission point and logistic regression model: 1
    • logistic regression model and low middle: 1, 2, 3, 4, 5, 6
    • logistic regression model and lung cancer: 1, 2, 3, 4, 5, 6